Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07779408 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study to Assess Safety and Immunogenicity of an Egg-based H5N8 Influenza Vaccine at Multiple Dose Levels Adjuvanted With Matrix-M in Healthy Participants 18 Years of Age and Above.

Name: Study to Assess Safety and Immunogenicity of an Egg-based H5N8 Influenza Vaccine at Multiple Dose Levels Adjuvanted With Matrix-M in Healthy Participants 18 Years of Age and Above. — clinical trial record (NCT07779408)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 1/2

SponsorSanofi

Started2026-08-10

View on ClinicalTrials.gov ↗

The study aims to evaluate an egg-based H5N8 influenza vaccine up to 3 dose levels (low, medium, and high dose) given with or without adjuvant to see if the adjuvant improves vaccine effectiveness. The study will enroll healthy adults aged 18 years and over. Participants will receive 2 injections in their arm of either one of the 3 dose levels of the study vaccine (low, medium, or high dose) with the adjuvant or the unadjuvanted vaccine (high dose). Study duration per participant: approximately 14 months (including screening visit).

Trial Details

NCT Number	NCT07779408
Lead Sponsor	Sanofi
Conditions	Healthy Volunteers, Influenza
Enrollment	640 participants
Start Date	2026-08-10
Primary Completion	2028-02-22 (estimated)
Study Completion	2028-02-22 (estimated)
Updated on ClinicalTrials.gov	2026-08-21